About Rubraca® (rucaparib)

Rubraca is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2 and 3 that we are developing in multiple tumor types, including ovarian, prostate and bladder cancers as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway. Clovis holds worldwide rights for Rubraca.

In the United States, Rubraca® (rucaparib) tablets is approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Rubraca is also approved for the treatment of adult patients with deleterious BRCA-mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. If you are in the U.S., please visit www.Rubraca.com for more information and click here for full Prescribing Information and additional Important Safety Information.

In the European Union, Rubraca is licensed as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy, regardless of BRCA status. Rubraca is also licensed for adult patients with platinum-sensitive, relapsed or progressive, BRCA-mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum-based chemotherapy. If you are a healthcare provider in Europe, click here to access the Rubraca (rucaparib) Summary of Product Characteristics on the European Medicines Agency website. Healthcare professionals should report any suspected adverse reactions via their national reporting systems.

Rubraca is an unlicensed medical product outside of the U.S. and Europe.

About Lucitanib

Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFRα/β), and fibroblast growth factor receptors 1 though 3 (FGFR1-3).

Based on recent data for a drug similar to lucitanib that inhibits these same pathways – when combined with a PD-1 inhibitor – Clovis is exploring a study that will combine lucitanib with a PD-(L)1 inhibitor. Clovis also intends to initiate a study of lucitanib in combination with rucaparib, based on encouraging data of VEGF and PARP inhibitors in combination.